Groundbreaking model predicts heart attack risk months in advance

Study introduces a novel biomarker-based model to predict imminent myocardial infarction (IMI), identifying key proteins and metabolites that could revolutionize early detection and prevention strategies.

Takeda outlines mid-stage narcolepsy data that prompted ‘rapid’ move into Phase 3

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

June 4, 2024

Adcetris Plus Chemo Effective in HIV-Related Hodgkin Lymphoma

Brentuximab vedotin (Adcetris) in combination with doxorubicin, vinblastine, and dacarbazine (AVD) was effective for patients with HIV-related stages II-IV classical Hodgkin lymphoma (cHL), according to

August 5, 2023

New radionuclide-based agent offers hope for treating a variety of cancers

A newly discovered radionuclide-based agent (CB-2PA-NT) has been shown to have high tumor uptake, sustained tumor retention, and high contrast in preclinical models, making it

June 28, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.